Coya Therapeutics, Inc. / Fundamentals
Income statement
- Net revenue
€365.45K - Cost of goods sold
€17.71K - Gross profit
€353.65K - SG&A expenses
€2.52B - R&D expenses
€3.17B - EBITDA
-€5.55B - D&A
€23.61K - EBIT
-€5.55B - Interest expenses
€0.00 - EBT
-€5.27B - Tax expenses
€0.00 - Net income
-€5.27B
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
-€622.14M - Changes in working capital
-€2.17M - Operating cash flow
-€7.43B - Capex
€21.58K - Other investing cash flow
-€21.58M - Net investing cash flow
-€21.55M - Total cash dividends paid
€0.00 - Issuance of common stock
€7.77M - Debt repayment
€0.00 - Other financing cash flow
€16.53M - Net financing cash flow
€24.83M - Foreign exchange effects
€0.00 - Net change in cash
-€7.41B - Cash at end of period
€25.68B - Free cash flow
-€7.43B
Balance sheet
- Cash and cash equivalents
€25.68B - Cash and short-term investments
€25.68B - Total receivables
€0.00 - Inventory
€0.00 - Other current assets
€3.17B - Total current assets
€28.85B - Property, plant & equipment
€21.50M - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€0.00 - Other non-current assets
€0.00 - Total non-current assets
€21.50M - Total assets
€28.87B - Accounts payable
€803.78K - Short-term debt
€0.00 - Other current liabilities
€3.88B - Total current liabilities
€3.88B - Long-term debt
€0.00 - Deferred tax liabilities
€0.00 - Other non-current liabilities
€553.34M - Total non-current liabilities
€553.34M - Total liabilities
€4.44B - Common stock
€1.44M - Retained earnings
-€46.72B - Other equity
€0.00 - Total equity
€24.43B - Total liabilities and shareholders' equity
€28.87B
Company information
- Market capitalization
€83.45M - Employees
8 - Enterprise Value
-€35.44B
Company ratios
- Gross margin
-
96.8% Much better than peer group: -220.6% - EBITDA margin
-
-1,518,638.2% Much worse than peer group: -1,412.1% - EBIT margin
-
-1,518,643.2% Much worse than peer group: -1,085.2% - EBT margin
-
-1,442,888.7% Much worse than peer group: 2,830.5% - Net margin
-
-1,442,718.7% Much worse than peer group: 1,711.3% - ROE
-
-21.6% Better than peer group: -36.4% - ROA
-
-18.3% Much better than peer group: -69.4% - Asset turnover
-
0.0% Even with peer group: 3.5% - FCF margin
-
-2,033,162.5% Much worse than peer group: 1,549.1% - FCF yield
-8,903.5% - Efficiency ratio
1,518,738.2% - Net sales per employee
-
€45.68K - Net income per employee
-
-€659.06M